CGON missed EPS expectations by 9.38%
May 15, 2025, 10:34 PM
0.00%
What does CGON do
CG Oncology, based in Irvine, California, focuses on developing bladder-sparing therapies for bladder cancer and went public on January 25, 2024. Its key candidates include cretostimogene and BOND-003, both targeting non-muscle invasive bladder cancer.
Cg Oncology (CGON) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cg Oncology's actual EPS was -$0.45, missing the estimate of -$0.41 per share, resulting in a -9.38% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.